Page last updated: 2024-12-08

aclacinomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aklavin: antibiotic prepared from culture liquids of streptomycete (A 1129); possessing antiphage activity; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aclacinomycin T : An anthracycline that is aklavinone having an alpha-L-rhodosaminyl residue attached at position 4 via a glycosidic linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID149755
CHEMBL ID3040622
CHEBI ID74351
MeSH IDM0057251

Synonyms (51)

Synonym
66676-88-8
unii-t87wn25bnw
t87wn25bnw ,
KBIO1_000681
DIVK1C_000681
SDCCGMLS-0066947.P001
ccris 2266
nsc 100290
1-deoxypyrromycin
doxypyrromycin
1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(dimethylamino)-alpha-l-lyxo-hexapyranosyl)oxy)-, methyl ester, (1r-(1-alpha,2-beta,4-beta))-
ma 144t1
aclacinomycin t
antibiotic ma 144t1
SPECTRUM_000814
SPECTRUM4_001837
NCGC00178922-01
siwenmycin
aclacinomycins ,
aclacinomycin
IDI1_000681
BSPBIO_001892
SPECTRUM5_000633
aklavin
KBIOGR_002540
KBIO3_001112
KBIO2_003862
KBIO2_006430
KBIO2_001294
KBIOSS_001294
SPBIO_000297
SPECTRUM3_000156
NINDS_000681
SPECTRUM2_000079
methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate
rhodosaminyl-aklavinone
60504-57-6
C18634
methyl (1r,2r,4s)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
CHEBI:74351 ,
aklavine
LJZPVWKMAYDYAS-QKKPTTNWSA-N
3vl ,
CHEMBL3040622
DTXSID30209246
Q27105019
methyl (1r,2r,4s)-4-(((2r,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
methyl (1r,2r,4s)-4-[(2s,4s,5s,6s)-4-dimethylamino-5-hydroxy-6-methyl- oxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1h-tetra cene-1-carboxylate
1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-3-(dimethylamino)-.alpha.-l-lyxo-hexopyranosyl)oxy)-, methyl ester, (1r,2r,4s)-
ma-144t1
AKOS040745468

Research Excerpts

Overview

Aclacinomycin (ACM) is an oncostatic substance on the family of the Anthracyclines, with a proven activity in human and rodents. It is a member of naturally occurring anthracyClines having three sugar moieties in the molecule.

ExcerptReferenceRelevance
"Aclacinomycin A (ACM-A) is an anthracycline antitumor agent widely used in clinical practice. "( Rethinking Biosynthesis of Aclacinomycin A.
Tian, P; Xu, Z, 2023
)
2.65
"Aclacinomycin is an antitumor anthracycline antibiotic isolated from the culture broth of Streptomyces galilaeus MA144-M1. "( [Studies on the stability of aclacinomycin hydrochloride. I. Stability of solution of aclacinomycin hydrochloride (author's transl)].
Inui, T; Miura, H; Mori, S; Oki, T; Shindo, N, 1980
)
2
"Aclacinomycin (ACR) is an anthracycline anticancer drug that shows marked effects in Adriamycin (ADM)-resistant tumors. "( Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
Dong, J; Johdo, O; Naito, M; Seimiya, H; Tatsuta, T; Tsuruo, T, 1995
)
1.99
"Aclacinomycin (ACM) is an oncostatic substance on the family of the Anthracyclines, with a proven activity in human and rodents. "( [Increase of proliferative and cytotoxic responses to alloantigenic stimulation of mouse spleen cells treated with aclacinomycin].
Bravo-Cuéllar, A; Leal-Delgadillo, A; Liu, XH; Martín-Ruíz, JL; Orbach-Arbouys, S; Puebla-Pérez, AM; Ramos-Pineda, R,
)
1.78
"Aclacinomycin is a member of naturally occurring anthracyclines having three sugar moieties in the molecule. "( Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
Kunimoto, S; Takeuchi, T; Umezawa, K, 1987
)
1.98

Treatment

ExcerptReferenceRelevance
"Treatment with aclacinomycin A had no effect on body weight, or femoral or splenic cellularity."( WEHI-3B D+ Y1 leukemia cells as a model system to assess the induction of differentiation in vivo.
Carman, MD; Gamba-Vitalo, C; Sartorelli, AC, 1989
)
0.62

Toxicity

ExcerptReferenceRelevance
" Cardiotoxicity is the most severe side effect of anthracycline administration."( [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Nesterov, VV; Shkolnik, EL; Shkolnik, LD; Varlan, GV; Vasyuk, YA, 2016
)
0.43

Compound-Compound Interactions

Intrapleural treatment with aclacinomycin combined with closed tube thoracostomy was used in 7 patients with malignant pleural effusion.

ExcerptReferenceRelevance
"Intrapleural treatment with aclacinomycin combined with closed tube thoracostomy was used in 7 patients with malignant pleural effusion."( [Efficacy of intrapleural treatment with aclacinomycin combined with closed tube thoracostomy for malignant pleural effusion].
Fujii, M; Fujita, Y; Ishimitsu, T; Okabe, K; Toki, H, 1984
)
0.83
" In this study, we aimed to investigate the synergistic cytotoxic effect of low-dose arsenic trioxide (As2O3) combined with aclacinomycin A (ACM) on the human AML cell lines KG-1a and HL-60, and to clarify the underlying mechanism."( Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis.
Bai, X; Guo, K; Guo, Z; He, H; He, X; Qiu, D; Wang, J; Weng, G; Xu, X; Ye, Y; Yi, W; Zhang, M; Zhou, R, 2015
)
0.89
"To investigate the therapeutic efficacy and side effects of treating patients with myelodysplastic syndrome-RAEB (MDS-RAEB) and with refractory acute myeloid leukemia (AML) by using decitabine combined with CAG regimen."( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015
)
0.42
" All the patients received decitabine combined with CAG regimen consisting of decitabine 20 mg/(m(2) · d), d 1-5; aclarubicin 10 mg/d, d 6-13; cytarabine 20 mg/d, d 6-19; G-CSF 300 µg/d, d 6-19."( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015
)
0.42
"Decitabine combined with CAG regimen is effective and safe for treatment of MDS-RAEB and refractory AML patients, which can prolong lives of patiens with refractory hematological diseases."( [Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" The schedule and dosage of the anthracycline antibiotic that produced the maximum prolongation of life had no effect on peripheral platelet levels or packed red cell volume."( WEHI-3B D+ Y1 leukemia cells as a model system to assess the induction of differentiation in vivo.
Carman, MD; Gamba-Vitalo, C; Sartorelli, AC, 1989
)
0.28
"Aclacinomycin (ACM), a new anthracycline antibiotic compound, was given intravenously q x 3 to 6 weeks in a dosage of 4 x 60 mg/4 days to 10 patients with metastasizing breast cancer and 5 patients with gastric carcinoma."( [Pilot studies with aclacinomycin in patients with breast cancer or gastrointestinal tumors].
Gössinger, H; Lenzhofer, R; Moser, K; Rainer, H; Schneeweiss, B, 1983
)
2.03
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (10)

ClassDescription
anthracyclineAnthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
aminoglycoside
deoxy hexoside
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
polyketideNatural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
tetracenequinones
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
zwitterionA neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (159)

TimeframeStudies, This Drug (%)All Drugs %
pre-199084 (52.83)18.7374
1990's37 (23.27)18.2507
2000's17 (10.69)29.6817
2010's14 (8.81)24.3611
2020's7 (4.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.87 (24.57)
Research Supply Index5.18 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (4.76%)5.53%
Reviews8 (4.76%)6.00%
Case Studies5 (2.98%)4.05%
Observational0 (0.00%)0.25%
Other147 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]